Mixed pH-sensitive polymeric micelles for combination drug delivery

Pharmaceutical Research

Volumn 27, Issue 11, 2010, Pages 2421-2432

  Bae, Younsoo ^a   Alani, Adam W G ^b   Rockich, Nicole C ^b   Lai, T S Z Chung ^b   Kwon, Glen S ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

combination chemotherapy; drug delivery; mixed micelles; pH controlled release; polymeric micelles

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; COPOLYMER; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HEAT SHOCK PROTEIN 90; MACROGOL; POLYASPARTIC ACID;

AQUEOUS SOLUTION; ARTICLE; CANCER INHIBITION; CHEMICAL BOND; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICELLIZATION; PARTICLE SIZE; PH; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLVENT EFFECT; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; POLYMERS;

EID: 78549293222     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0234-3     Document Type: Article

References (41)

1. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
2. KSM Smalley NK Haass PA Brafford M Lioni KT Flaherty M Herlyn 2006 Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol Cancer Ther. 5 1136 1144 1:CAS:528:DC%2BD28XltVWntbo%3D 10.1158/1535-7163.MCT-06-0084 16731745 (Pubitemid 43881305)
3. CD Scripture WD Figg 2006 Drug interactions in cancer therapy Nat Rev Cancer 6 546 558 1:CAS:528:DC%2BD28XmtFehu7s%3D 10.1038/nrc1887 16794637 (Pubitemid 43980543)
4. W Xu L Neckers 2007 Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells Clin Cancer Res. 13 1625 1629 1:CAS:528:DC%2BD2sXivV2gsbc%3D 10.1158/1078-0432.CCR-06-2966 17363512 (Pubitemid 46952925)
5. Q Yao B Weigel J Kersey 2007 Synergism between etoposide and 17-AAG in leukemia cells: critical roles for hsp90, FLT3, topoisomerase II, Chk1, and Rad51 Clin Cancer Res. 13 1591 1600 1:CAS:528:DC%2BD2sXitlSjtLY%3D 10.1158/1078-0432.CCR-06-1750 17332306 (Pubitemid 46450452)
6. J Beliakoff L Whitesell 2004 Hsp90: an emerging target for breast cancer therapy Anticancer drugs 15 651 662 1:CAS:528:DC%2BD2cXlvValtbY%3D 10.1097/01.cad.0000136876.11928.be 15269596 (Pubitemid 39099914)
7. MP Goetz DO Toft MM Ames C Erlichman 2003 The hsp90 chaperone complex as a novel target for cancer therapy Ann Oncol. 14 1169 1176 1:STN:280: DC%2BD3szkvVaktA%3D%3D 10.1093/annonc/mdg316 12881371 (Pubitemid 37039035)
8. JH Atkins LJ Gershell 2002 Selective anticancer drugs Nat Rev Cancer 2 645 646 1:CAS:528:DC%2BD38XmslamsbY%3D 10.1038/nrc900
9. KR Hande 1998 Clinical applications of anticancer drugs targeted to topoisomerase II Biochim Biophys Acta 1400 173 184 1:CAS:528:DyaK1cXmtFWis74%3D 9748560
10. PS Senter J Kopecek 2004 Drug carriers in medicine and biology Mol Pharm. 1 395 398 1:CAS:528:DC%2BD2cXptlOiu70%3D 10.1021/mp040010x 16028350
11. R Duncan 2006 Polymer conjugates as anticancer nanomedicines Nat Rev Cancer 6 688 701 1:CAS:528:DC%2BD28XosVOmsLY%3D 10.1038/nrc1958 16900224 (Pubitemid 44286001)
12. MJ Vicent F Greco RI Nicholson A Paul PC Griffiths R Duncan 2005 Polymer therapeutics designed for a combination therapy of hormone-dependent cancer Angew Chem Int Ed. 44 4061 4066 1:CAS:528:DC%2BD2MXmtF2gsrY%3D 10.1002/anie.200462960 (Pubitemid 40886448)
13. J Kopecek P Kopeckova T Minko ZR Lu 2000 HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action Eur J Pharm Biopharm. 50 61 81 1:CAS:528:DC%2BD3cXjslyisr4%3D 10.1016/S0939-6411(00)00075-8 10840193 (Pubitemid 30326689)
14. Y Bae K Kataoka 2009 Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers Adv Drug Deliver Rev. 61 768 784 1:CAS:528:DC%2BD1MXnsl2gtb8%3D 10.1016/j.addr.2009.04.016
15. N Nishiyama Y Bae K Miyata S Fukushima K Kataoka 2005 Smart polymeric micelles for gene and drug delivery Drug Discov. Today: Technologies 2 21 26 1:CAS:528:DC%2BD2MXpvFOmt7w%3D 10.1016/j.ddtec.2005.05.007 (Pubitemid 40946304)
16. K Kataoka GS Kwon M Yokoyama T Okano Y Sakurai 1993 Block copolymer micelles as vehicles for drug delivery J Control Release 24 119 132 1:CAS:528:DyaK3sXltVejt7g%3D 10.1016/0168-3659(93)90172-2 (Pubitemid 23161325)
17. Y Bae TA Diezi A Zhao GS Kwon 2007 Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents J Control Release 122 324 330 1:CAS:528: DC%2BD2sXhtVKrsL3F 10.1016/j.jconrel.2007.05.038 17669540 (Pubitemid 47404677)
18. ML Forrest A Zhao CY Won AW Malick GS Kwon 2006 Lipophilic prodrugs of hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b- poly(caprolactone) micelles J Control Release 116 139 149 1:CAS:528: DC%2BD28Xht12jtLzI 10.1016/j.jconrel.2006.07.003 16926059 (Pubitemid 44854279)
19. Y Bae RA Buresh TP Williamson THH Chen DY Furgeson 2007 Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin J Control Release 122 16 23 1:CAS:528:DC%2BD2sXpsV2rtLk%3D 10.1016/j.jconrel.2007.06.005 17651857 (Pubitemid 47284549)
20. P Workman MV Powers 2007 Chaperoning cell death: a critical dual role for hsp90 in small-cell lung cancer Nat Chem Biol. 3 455 457 1:CAS:528: DC%2BD2sXnvFaqsLg%3D 10.1038/nchembio0807-455 17637775 (Pubitemid 47080382)
21. E Pick Y Kluger JM Giltnane C Moeder RL Camp DL Rimm HM Kluger 2007 High hsp90 expression is associated with decreased survival in breast cancer Cancer Res. 67 2932 2937 1:CAS:528:DC%2BD2sXksVGlt7c%3D 10.1158/0008-5472.CAN-06-4511 17409397 (Pubitemid 46724827)
22. JC Young I Moarefi FU Hartl 2001 Hsp90: a specialized but essential protein-folding tool J Cell Biol. 154 267 273 1:CAS:528:DC%2BD3MXlsVOjs7k%3D 10.1083/jcb.200104079 11470816 (Pubitemid 34286138)
23. CR Barker AV McNamara SA Rackstraw DE Nelson MR White AJM Watson JR Jenkins 2006 Inhibition of hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage Nucleic Acids Res. 34 1148 1157 1:CAS:528:DC%2BD28XitVOqur0%3D 10.1093/nar/gkj516 16504968
24. Y Bae WD Jang N Nishiyama S Fukushima K Kataoka 2005 Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery Mol BioSyst. 1 242 250 1:CAS:528:DC%2BD2MXhtFWitrrF 10.1039/b500266d 16880988 (Pubitemid 41442434)
25. Y Kasuya ZR Lu P Kopeckova T Minko SE Tabibi J Kopecek 2001 Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates J Control Release 74 203 211 1:CAS:528:DC%2BD3MXlslans7g%3D 10.1016/S0168-3659(01)00318-2 11489496 (Pubitemid 32727622)
26. C DeBoer PA Meulman RJ Wnuk DH Peterson 1970 Geldanamycin, a new antibiotic J Antibiot. 23 442 447 1:CAS:528:DyaE3MXhtFyltQ%3D%3D 5459626
27. Y Bae S Fukushima A Harada K Kataoka 2003 Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change Angew Chem Int Ed. 42 4640 4643 1:CAS:528:DC%2BD3sXot12ltb0%3D 10.1002/anie.200250653 (Pubitemid 37271305)
28. Y Bae N Nishiyama S Fukushima H Koyama Y Matsumura K Kataoka 2005 Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: Tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjugate Chem. 16 122 130 1:CAS:528:DC%2BD2cXhtFSlur3K 10.1021/bc0498166 (Pubitemid 40129685)
29. L Xiao P Rasouli DM Ruden 2007 Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs Curr Med Chem. 14 223 232 1:CAS:528:DC%2BD2sXitlamsrw%3D 10.2174/092986707779313372 17266581 (Pubitemid 46043917)
30. A Kamal L Thao J Sensintaffar L Zhang MF Boehm LC Fritz FJ Burrows 2003 A high affinity conformation of hsp90 confers tumour selectivity on hsp90 inhibitors Nature 425 357 359 10.1038/nature01913 (Pubitemid 37187270)
31. JM Fortune N Osheroff 2000 Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog Nucleic Acid Res Mol Biol. 64 221 253 1:CAS:528:DC%2BD3cXivVCnsLw%3D 10.1016/S0079-6603(00)64006-0 10697411
32. AWG Alani Y Bae D Rao GS Kwon 2010 Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel Biomaterials 31 1765 1772 1:CAS:528:DC%2BC3cXjtVSmtA%3D%3D 10.1016/j.biomaterials.2009.11.038 19959225
33. KR West S Otto 2005 Reversible covalent chemistry in drug delivery Curr Drug Discov Technol. 2 123 160 1:CAS:528:DC%2BD2MXpslOgu78%3D 10.2174/1570163054866882 16472224 (Pubitemid 41242960)
34. C Barker J Hamlett SR Pennington F Burrows K Lundgren R Lough AJM Watson JR Jenkins 2006 The topoisomerase II-hsp90 complex: a new chemotherapeutic target Int J Cancer 118 2685 2693 1:CAS:528:DC%2BD28Xks1Sis78%3D 10.1002/ijc.21717 16385570 (Pubitemid 43673345)
35. G Kersting MV Tzvetkov K Huse B Kulle V Hafner J Brockmoller L Wojnowski 2006 Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells N-S Arch Pharmacol. 374 21 30 1:CAS:528:DC%2BD28Xht1KisrbP 10.1007/s00210-006-0091-0
36. M Martin-Richard M Munoz J Albanell L Colomo M Bellet MJ Rey J Tabernero C Alonso A Cardesa P Gascon PL Fernandez 2004 Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy Oncology 66 388 394 1:CAS:528:DC%2BD2cXntFSgt74%3D 10.1159/000079487 15331926 (Pubitemid 39194361)
37. D Burgess J Doles L Zender W Xue B Ma W McCombie GJ Hannon SW Lowe MT Hemann 2008 Topoisomerase levels determine chemotherapy response in vitro and in vivo PNAS 105 9053 9058 10.1073/pnas.0803513105 18574145
38. JT Chang Y-C Lu Y-J Chen C-P Tseng Y-L Chen C-W Fang A-J Cheng 2006 hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells Brit J Cancer 94 870 878 1:CAS:528:DC%2BD28Xis1GktL4%3D 10.1038/sj.bjc.6603008 16508638
39. K Yoshida T Yamaguchi H Shinagawa N Taira KI Nakayama Y Miki 2006 Protein kinase C δ activates topoisomerase IIδ to induce apoptotic cell death in response to DNA damage Mol Cell Biol. 26 3414 3431 1:CAS:528: DC%2BD28XksVKks7k%3D 10.1128/MCB.26.9.3414-3431.2006 16611985
40. MV Powers P Workman 2007 Inhibitors of the heat shock response: biology and pharmacology FEBS Lett. 581 3758 3769 1:CAS:528:DC%2BD2sXotlaisbo%3D 10.1016/j.febslet.2007.05.040 17559840 (Pubitemid 47081010)
41. SC Biship JA Burlison BSJ Blagg 2007 Hsp90: a novel target for the disruption of multiple signaling cascades Curr Cancer Drug Tar. 7 369 388 10.2174/156800907780809778 (Pubitemid 46849241)